Biohaven Pharmaceutical

About:

Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.

Top Investors: Royalty Pharma, RA Capital Management, HighlightLL Pharma, Connecticut Innovations, Venrock

Description:

Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

Total Funding Amount:

$1.69B

Headquarters Location:

New Haven, Connecticut, United States

Founded Date:

2013-01-01

Founders:

Rob Berman

Number of Employees:

1001-5000

Last Funding Date:

2024-09-30